Articles

Find an Article

Filter articles

Applied Filters

Showing 251 to 260 of 319 results

The bitter pill of fake medicine

International30-01-2015

The most recent Illicit Trade Report states that pharmaceuticals are by far the most numerous counterfeit commodity reported, and the problem is increasing. LSIPR investigates what’s being done about it.

After Alice: the two-step rule

US30-01-2015Judith Kim and Scott Schaller

Existing portfolios should be carefully reviewed and care must be taken in drafting new patent applications to withstand section 101 scrutiny in the US, as Judith Kim, director, and Scott Schaller, of counsel, at Sterne Kessler Goldstein & Fox, describe.

Global patents: innovation leads to growth

International30-01-2015Bob Stembridge

Despite the headwinds facing the industry, a growing number of leading pharmaceutical companies feature on Thomson Reuters’ annual Top 100 Global Innovators list, as Bob Stembridge reports.

Bulletproofing pharma patents

US19-12-2014Christine Goddard and Janis Fraser

Maximising the strength of patent protection should be an important objective of any R&D pharma company. Christine Goddard and Janis Fraser of law firm Fish & Richardson offer their six top tips for success.

Wearable technology: seeing the future

US27-11-2014

Google’s new contact lens sensor is just one of the latest eye-based devices that has vast potential in the field of medicine. LSIPR reports.

Patent decisions: a clash of the courts

US27-11-2014Felicia Boyd

The US Supreme Court has now heard arguments in the appeal of Teva v Sandoz from the US Court of Appeals for the Federal Circuit. This could fundamentally change how patent decisions are reviewed by the Federal Circuit and the deference given to district court rulings, says Felicia Boyd of Barnes & Thornburg.

Apotex appeal: cold feet in Canada

Canada27-11-2014Gunars Gaikis

The Supreme Court of Canada was expected to bring the Canadian law on utility more into line with other jurisdictions, but those hopes have now received a setback, as Gunars Gaikis of Smart & Biggar/Fetherstonhaugh reports.

Pursuing agribusiness infringement actions in Brazil

Brazil04-11-2014Gabriel Di Blasi

Protecting rights related to desirable plant species is a delicate process, says Gabriel Di Blasi.

A changing landscape: approving biosimilar products in Mexico

Mexico03-11-2014José Trigueros

Who has legal interest in the grant of sanitary registrations for follow-on biologics? José Trigueros examines a recent case in Mexico that could have far-reaching ramifications.

Insurance 
companies v AstraZeneca

UK, US03-11-2014Jason Rutt

Jason Rutt considers the impact AstraZeneca’s recent US pay-for-delay case will have on the industry.

Showing 251 to 260 of 319 results

LSIPR